Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 195.24 USD 2.84% Market Closed
Market Cap: 41.6B USD

Intrinsic Value

The intrinsic value of one INSM stock under the Base Case scenario is 109.32 USD. Compared to the current market price of 195.24 USD, Insmed Inc is Overvalued by 44%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

INSM Intrinsic Value
109.32 USD
Overvaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Insmed Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about INSM?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is INSM valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Insmed Inc.

Explain Valuation
Compare INSM to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Arikayce drives most of the company’s current revenue, leaving Insmed vulnerable to market changes or competing treatments that could quickly erode its core earnings base.

Should Brensocatib’s late-stage clinical trials falter or face regulatory hurdles, it would undermine a key growth driver and significantly dampen Insmed’s future prospects.

Cash burn from multiple pipeline initiatives and reliance on external funding increase the risk of shareholder dilution, especially if clinical timelines slip or commercial returns fall short.

Bull Theses

Continued geographic expansion and potential label extensions for Arikayce could substantially increase its patient reach, reinforcing revenue growth and reducing the company’s reliance on additional funding.

Brensocatib has the potential to become a first-in-class therapy for multiple inflammatory lung conditions, providing a sizable new revenue stream and diversifying Insmed’s portfolio beyond infectious disease.

Insmed’s focus on rare and serious illnesses, coupled with a strong research pipeline (including TPIP), positions it to secure advantageous regulatory designations and partnerships that could enhance global market penetration.

Show More Less
How do you feel about INSM?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Insmed Inc

Current Assets 1.9B
Cash & Short-Term Investments 1.7B
Receivables 65.3m
Other Current Assets 186.6m
Non-Current Assets 428.9m
PP&E 116.6m
Intangibles 220.7m
Other Non-Current Assets 91.6m
Current Liabilities 417.2m
Accounts Payable 163.3m
Accrued Liabilities 250.7m
Other Current Liabilities 3.2m
Non-Current Liabilities 998m
Long-Term Debt 725.2m
Other Non-Current Liabilities 272.8m
Efficiency

Free Cash Flow Analysis
Insmed Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Insmed Inc

Revenue
447m USD
Cost of Revenue
-104.9m USD
Gross Profit
342.2m USD
Operating Expenses
-1.3B USD
Operating Income
-990.3m USD
Other Expenses
-193.6m USD
Net Income
-1.2B USD
Fundamental Scores

INSM Profitability Score
Profitability Due Diligence

Insmed Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
ROE is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
31/100
Profitability
Score

Insmed Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

INSM Solvency Score
Solvency Due Diligence

Insmed Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Low D/E
61/100
Solvency
Score

Insmed Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INSM Price Targets Summary
Insmed Inc

Wall Street analysts forecast INSM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INSM is 217.33 USD with a low forecast of 145.65 USD and a high forecast of 268.8 USD.

Lowest
Price Target
145.65 USD
25% Downside
Average
Price Target
217.33 USD
11% Upside
Highest
Price Target
268.8 USD
38% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Insmed Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for INSM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

INSM Insider Trading
Buy and sell transactions by insiders

INSM News

Other Videos
What is the Intrinsic Value of one INSM stock?

The intrinsic value of one INSM stock under the Base Case scenario is 109.32 USD.

Is INSM stock undervalued or overvalued?

Compared to the current market price of 195.24 USD, Insmed Inc is Overvalued by 44%.

Back to Top